Voyager Therapeutics Provides Second Quarter 2016 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Voyager Therapeutics (VYGR) Reports Q2 Loss of $0.37/Share
August 11, 2016 7:07 AM EDTVoyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.37), versus ($5.94) reported last year.
Voyager reported cash, cash equivalents and marketable securities of $204.0 million as of June 30, 2016. Voyager continues to expect to end 2016 with cash, cash equivalents and marketable securities of $160.0 million and that its existing... More
